Summary
This 2022 update from the American Association of Clinical Endocrinology establishes comprehensive clinical standards for developing individualised diabetes mellitus care plans, integrating current evidence on glycaemic management, cardiovascular and renal risk reduction. As a clinical guideline synthesising existing evidence rather than primary research, it provides practitioner decision-support recommendations across the diabetes care pathway. The document reflects current clinical consensus on evidence-based diabetes management informed by peer-reviewed literature.
Regional applicability
UK clinicians may find relevant evidence-based recommendations, though application requires consideration of NHS commissioning pathways, NICE guidance alignment, and differences in medication availability and healthcare system structures. The guideline's emphasis on individualised care planning aligns with contemporary UK diabetes care principles.
Key measures
Glycaemic control targets; cardiovascular risk markers; renal function parameters; diabetes-related complication prevention metrics
Outcomes reported
The guideline synthesises evidence-based recommendations for individualised diabetes care planning, including glycaemic management targets, cardiovascular and renal risk reduction strategies, and prevention of diabetes-related complications. It provides practitioner-facing clinical standards to inform decision-making across the diabetes care pathway.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.